SYNGR4 Antibody

What is SYNGR4 and why is it important in research?

SYNGR4 (Synaptogyrin 4) is a protein that has gained significant research interest due to its dual role in neurological disorders and cancer biology. It is considered one of the causative genes for amyotrophic lateral sclerosis and has recently been implicated in breast cancer development. SYNGR4 is highly expressed in various malignant tumors and affects cancer prognosis through multiple mechanisms including organelle fission, chromosome segregation, and nuclear division. The protein's impact on immune cell infiltration within tumors, particularly its ability to influence tumor-associated macrophage polarization, makes it a promising target for cancer immunotherapy research .

What types of SYNGR4 antibodies are available for research applications?

Multiple types of SYNGR4 antibodies are available for research, varying in their binding specificity, host species, clonality, and conjugation status. Common variants include:

These antibodies are typically purified using techniques such as ammonium sulfate precipitation followed by antigen affinity chromatography or Protein A purification .

How do I select the appropriate SYNGR4 antibody for my specific experimental needs?

Selection of the appropriate SYNGR4 antibody depends on several experimental factors. For Western blotting and ELISA applications studying human samples, an anti-SYNGR4 N-Term antibody from goat would be suitable. For immunofluorescence or immunohistochemistry in mouse models, rabbit polyclonal antibodies targeting the AA 111-200 region are recommended. When designing multiplexed immunofluorescence experiments, consider fluorophore-conjugated antibodies that align with your microscopy setup's filter capabilities. For experiments requiring signal amplification, HRP-conjugated antibodies would be advantageous. Always verify cross-reactivity with your species of interest, as some antibodies show predicted reactivity with human and rat samples beyond their validated reactivity .

What are the optimal conditions for using SYNGR4 antibodies in Western blotting experiments?

When conducting Western blotting with SYNGR4 antibodies, researchers should optimize several parameters to ensure reliable results. Based on the antibody specifications and research practices, a general protocol would include:

• Sample preparation: Extract proteins using RIPA buffer with protease inhibitors

• Protein quantification: Use Bradford or BCA assay to standardize loading (20-30 μg per lane)

• Gel electrophoresis: 10-12% SDS-PAGE is typically suitable

• Transfer: Use PVDF membrane for optimal protein binding

• Blocking: 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Primary antibody: Dilute SYNGR4 antibody 1:500 to 1:1000 in blocking solution and incubate overnight at 4°C

• Washing: 3-5 washes with TBST

• Secondary antibody: Species-appropriate HRP-conjugated secondary (or direct HRP-conjugated primary) at 1:2000-1:5000 for 1 hour at room temperature

• Detection: ECL substrate and imaging system or X-ray film

Optimization might be necessary for each specific antibody, particularly regarding dilution factors and incubation times .

How can SYNGR4 antibodies be effectively used in immunohistochemistry applications?

For effective immunohistochemistry (IHC) with SYNGR4 antibodies, researchers should follow these methodological considerations:

• Sample preparation:

  • For paraffin-embedded sections: Standard fixation in 10% neutral-buffered formalin, paraffin embedding, sectioning at 4-6 μm

  • For frozen sections: OCT embedding, cryosectioning at 8-10 μm

• Antigen retrieval: Heat-mediated antigen retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Blocking: 3-5% normal serum (from the same species as the secondary antibody) with 0.1-0.3% Triton X-100

• Primary antibody: Apply SYNGR4 antibody at optimized dilution (typically 1:100 to 1:500) and incubate overnight at 4°C

• Detection system:

  • For unconjugated antibodies: Appropriate secondary antibody followed by DAB or AEC chromogen

  • For HRP-conjugated antibodies: Direct detection with chromogen

  • For fluorophore-conjugated antibodies: Direct visualization

• Counterstaining: Hematoxylin for brightfield or DAPI for fluorescence

• Controls: Include both negative controls (omitting primary antibody) and positive controls (tissue known to express SYNGR4)

This approach has been successfully used to evaluate SYNGR4 expression in various tumor tissues, including breast cancer specimens .

What methods can be used to validate SYNGR4 antibody specificity?

Validating antibody specificity is crucial for reliable research outcomes. For SYNGR4 antibodies, multiple validation approaches are recommended:

• Western blot analysis: Confirm a single band of appropriate molecular weight (~22-25 kDa for SYNGR4)

• RNA interference: Use siRNA knockdown to reduce SYNGR4 expression and confirm corresponding reduction in antibody signal. Research has demonstrated successful SYNGR4 knockdown in breast cancer cell lines (SKBRE3, MCF-7, and MDA-MB-231) using targeted siRNAs, with knockdown confirmation by both Western blot and functional assays

• Knockout/overexpression models: Compare antibody signals in cells or tissues with genetic manipulation of SYNGR4

• Peptide competition: Pre-incubate antibody with immunizing peptide before application to samples

• Cross-reactivity testing: Test antibody across multiple species and tissues based on sequence homology

• Comparison with orthogonal methods: Correlate protein detection with mRNA expression data from qPCR or RNA-seq

• Multiple antibody concordance: Compare results using antibodies targeting different epitopes of SYNGR4

Rigorous validation ensures that observed signals truly represent SYNGR4 protein rather than non-specific binding or cross-reactivity .

How can SYNGR4 antibodies be used to investigate immune cell infiltration in tumor microenvironments?

SYNGR4 antibodies can be instrumental in elucidating the relationship between SYNGR4 expression and immune cell infiltration in tumor microenvironments, particularly in breast cancer. A comprehensive approach would involve:

• Multiplex immunofluorescence: Employ SYNGR4 antibodies alongside immune cell markers (CD68 for macrophages, CD8 for cytotoxic T cells, CD4 for helper T cells) to simultaneously visualize SYNGR4 expression and immune cell populations within tumor sections. Fluorophore-conjugated SYNGR4 antibodies are particularly useful for this application .

• Flow cytometry: Use cell isolation protocols followed by SYNGR4 antibody staining to quantify expression levels in various tumor and immune cell populations. Research has shown that SYNGR4 knockdown influences macrophage polarization toward M1 phenotype, which can be assessed using flow cytometry to analyze macrophages in tumors .

• Tissue microarray analysis: Apply SYNGR4 antibodies to tissue microarrays to correlate expression with immune infiltration across numerous patient samples.

• Cell sorting and co-culture systems: Isolate cell populations based on SYNGR4 expression using antibody-based sorting, then analyze immune interactions in co-culture systems. Researchers have developed co-culture models where breast cancer cells interact with tumor-associated macrophages to mimic the tumor immune microenvironment, demonstrating that SYNGR4 knockdown promotes M1 polarization of macrophages .

• Spatial transcriptomics integration: Combine SYNGR4 immunohistochemistry with spatial transcriptomics to correlate protein expression with gene expression signatures of immune infiltration.

These approaches have revealed that SYNGR4 overexpression affects immune cell infiltration in breast cancer, with increased Th2 cell infiltration and decreased Tcm, macrophages, and CD8-positive T cells .

What role does SYNGR4 play in breast cancer development and how can antibodies help elucidate this mechanism?

SYNGR4 has emerged as a significant player in breast cancer development through multiple mechanisms, which can be investigated using antibody-based approaches:

• Expression profiling: SYNGR4 antibodies enable quantification of protein expression across breast cancer subtypes, cell lines, and patient samples. Studies have shown significantly higher SYNGR4 expression in breast cancer cell lines (SKBRE3, MCF-7, and MDA-MB-231) compared to normal breast cells (MCF-10A) .

• Mechanistic studies: Immunoprecipitation using SYNGR4 antibodies can identify protein-protein interactions mediating SYNGR4's effects on organelle fission, chromosome segregation, and nuclear division.

• Functional analysis with knockdown validation: After SYNGR4 knockdown, antibodies can confirm reduced protein levels while functional assays assess effects on:

  • Cell proliferation (reduced proliferation observed in colony formation and CCK8 assays)

  • Migration capacity (decreased migration in Transwell and scratch assays)

  • Tumorigenicity in vivo (reduced tumor growth in mouse models)

• Immune microenvironment modulation: SYNGR4 antibodies combined with macrophage markers reveal that SYNGR4 knockdown promotes tumor-associated macrophage polarization toward the M1 phenotype rather than M2, evidenced by:

  • Increased pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)

  • Decreased anti-inflammatory cytokines (IL-4, IL-10)

  • Elevated M1 markers (iNOS) and reduced M2 markers (Arg-1)

• Therapeutic target assessment: SYNGR4 antibodies can evaluate potential therapeutic interventions aimed at modulating SYNGR4 expression or function.

These research applications have collectively demonstrated that SYNGR4 overexpression promotes breast cancer proliferation, migration, and creates an immunosuppressive microenvironment favorable for tumor growth .

How can SYNGR4 antibodies be utilized in investigating the connection between SYNGR4 and amyotrophic lateral sclerosis?

While SYNGR4 has been identified as a potential causative gene for amyotrophic lateral sclerosis (ALS), this connection remains less explored than its role in cancer. SYNGR4 antibodies can facilitate investigation of this relationship through:

• Expression mapping in neuronal tissues: Utilize immunohistochemistry with SYNGR4 antibodies to characterize expression patterns in motor neurons and surrounding glial cells in normal and ALS-affected tissues.

• Protein localization studies: Employ subcellular fractionation followed by Western blotting with SYNGR4 antibodies to determine protein localization within neuronal cells, particularly at synaptic terminals where synaptogyrin family proteins typically function.

• Co-localization with ALS-associated proteins: Perform dual immunofluorescence using SYNGR4 antibodies alongside antibodies against known ALS-associated proteins (SOD1, TDP-43, FUS) to identify potential interactions or pathological co-aggregation.

• Mouse model characterization: Apply SYNGR4 antibodies to study protein expression and distribution in transgenic mouse models of ALS, correlating with disease progression.

• Patient sample analysis: Compare SYNGR4 expression patterns in post-mortem tissue samples from ALS patients versus controls using immunohistochemistry techniques.

• Functional studies in neuronal cultures: After genetic manipulation of SYNGR4 in primary motor neurons or neuronal cell lines, use antibodies to confirm altered expression levels while assessing functional outcomes relevant to ALS pathophysiology.

This area represents an important research direction given the established role of SYNGR4 as a causative gene in ALS, though studies specifically applying these techniques in ALS research are still emerging .

What are common challenges when using SYNGR4 antibodies and how can they be overcome?

Researchers working with SYNGR4 antibodies may encounter several technical challenges. Here are evidence-based solutions for addressing these issues:

• High background in immunohistochemistry:

  • Increase blocking duration (2-3 hours) and concentration (5-10% normal serum)

  • Optimize antibody dilution (perform titration series)

  • Include 0.1-0.3% Triton X-100 in blocking solution to reduce non-specific binding

  • Extend washing steps (5-6 washes of 5 minutes each)

• Weak or absent signal in Western blotting:

  • Ensure adequate protein loading (30-50 μg per lane)

  • Optimize antibody concentration (try 1:250 to 1:1000 dilutions)

  • Enhance antigen availability through complete denaturation

  • Increase exposure time during detection

  • Confirm sample preparation maintains protein integrity (use fresh protease inhibitors)

• Cross-reactivity issues:

  • Pre-absorb antibody with non-specific proteins

  • Perform peptide competition assays to confirm specificity

  • Choose antibodies validated for your specific species and application

• Inconsistent results in immunofluorescence:

  • Standardize fixation protocols (4% paraformaldehyde for 15-20 minutes)

  • Optimize permeabilization (0.2% Triton X-100 for 10 minutes)

  • Use antigen retrieval methods (citrate buffer, pH 6.0)

  • Mount with anti-fade reagent to prevent photobleaching

• Difficulties in co-culture models:

  • Clearly distinguish cell populations (use cell trackers or fluorescent proteins)

  • Optimize cell ratios when studying SYNGR4's effect on macrophage polarization

  • Use appropriate controls for each cell type individually

How should researchers interpret conflicting SYNGR4 antibody data across different experimental platforms?

When confronted with conflicting SYNGR4 antibody data across different experimental platforms, researchers should follow this systematic approach to interpretation:

• Evaluate antibody characteristics:

  • Different epitope targets (N-terminal vs. AA 111-200) may yield varying results based on protein conformation, post-translational modifications, or protein-protein interactions

  • Host species and clonality differences can affect specificity and sensitivity

  • Conjugation status may influence detection threshold

• Consider methodological differences:

  • Compare fixation methods across immunohistochemistry experiments

  • Analyze protein extraction protocols in Western blotting

  • Evaluate blocking agents and washing stringency

• Integrate orthogonal validation:

  • Correlate protein data with mRNA expression (qPCR, RNA-seq)

  • Use multiple antibodies targeting different epitopes

  • Employ genetic manipulation (siRNA, CRISPR) to create negative controls

• Normalize quantitative data appropriately:

  • Use consistent loading controls for Western blots

  • Apply same image acquisition settings for immunofluorescence

  • Account for varying antibody sensitivities when comparing absolute values

• Consider biological context:

  • Cell type-specific expression patterns may explain differences

  • Subcellular localization might vary across experimental systems

  • Altered SYNGR4 function in disease states could affect antibody binding

• Statistical analysis:

  • Apply appropriate statistical tests to determine significance of differences

  • Consider technical and biological replicates separately

  • Perform power analysis to ensure adequate sample sizes

Research has shown that SYNGR4 expression patterns differ between cancer cell lines and normal cells, and that knockdown experiments can validate antibody specificity across multiple experimental platforms .

What advanced analytical approaches can be used to correlate SYNGR4 expression with immune infiltration data?

Integrating SYNGR4 expression data with immune infiltration requires sophisticated analytical approaches:

• Bioinformatic analysis of public databases:

  • Use GSVA (Gene Set Variation Analysis) to assess immune cell infiltration patterns in relation to SYNGR4 expression

  • Apply TCGA and GTEx database analysis to correlate SYNGR4 expression with immune signatures across cancer types

  • Implement the TIDE algorithm to predict immunotherapy responsiveness based on SYNGR4 expression levels

• Single-cell analysis integration:

  • Correlate SYNGR4 expression with immune cell populations at single-cell resolution

  • Create trajectory analyses to understand developmental relationships

  • Generate cell-cell interaction maps based on receptor-ligand pairs

• Spatial analysis techniques:

  • Apply multiplex immunofluorescence with SYNGR4 antibodies and immune markers

  • Implement digital spatial profiling to quantify protein expression in defined tissue regions

  • Utilize neighborhood analysis to identify spatial relationships between SYNGR4-expressing cells and immune populations

• Machine learning approaches:

  • Develop predictive models incorporating SYNGR4 expression and immune features

  • Use unsupervised clustering to identify patient subgroups with similar SYNGR4/immune profiles

  • Apply deep learning to image analysis for automated quantification of immune infiltration

• Multi-omics integration:

  • Correlate SYNGR4 protein levels with transcriptomic, genomic, and epigenomic data

  • Perform pathway enrichment analysis to identify mechanisms linking SYNGR4 to immune regulation

  • Construct protein-protein interaction networks centered on SYNGR4

Research has demonstrated that breast cancers with SYNGR4 overexpression showed increased Th2 cell infiltration and decreased Tcm, macrophages, and CD8-positive T cells. Furthermore, SYNGR4 overexpression was associated with higher predicted responsiveness to immunotherapy based on the TIDE algorithm, suggesting complex relationships between SYNGR4 expression and immune function in the tumor microenvironment .

What emerging technologies might enhance SYNGR4 antibody applications in research?

Emerging technologies are poised to revolutionize SYNGR4 antibody applications in several ways:

• Advanced imaging technologies:

  • Super-resolution microscopy to visualize SYNGR4 localization at nanoscale resolution

  • Live-cell imaging with tagged antibody fragments to track SYNGR4 dynamics in real-time

  • Expansion microscopy to physically enlarge specimens for improved visualization of SYNGR4 in complex cellular structures

• Antibody engineering advancements:

  • Development of single-domain nanobodies against SYNGR4 for improved tissue penetration

  • Bispecific antibodies targeting SYNGR4 and immune cell markers simultaneously

  • Site-specific conjugation technologies for precise fluorophore or enzyme attachment

• Three-dimensional model systems:

  • Application of SYNGR4 antibodies in advanced organoid cultures to better recapitulate in vivo conditions

  • Integration with microfluidic organ-on-chip platforms to study SYNGR4 in dynamic environments

  • Implementation in 3D bioprinted tumor models to assess spatial distribution

• High-throughput and multiplexed approaches:

  • Mass cytometry (CyTOF) incorporating SYNGR4 antibodies for single-cell proteomic profiling

  • Multiplexed ion beam imaging (MIBI) for simultaneous detection of dozens of proteins including SYNGR4

  • DNA-barcoded antibody technologies for ultra-high-parameter analysis

• In situ protein analysis:

  • Proximity ligation assays to detect SYNGR4 interactions with potential binding partners

  • In situ sequencing combined with immunofluorescence to correlate SYNGR4 protein with gene expression

These technological advances will enable more comprehensive investigation of SYNGR4's role in both cancer biology and neurological disorders, potentially revealing new therapeutic targets and biomarkers .

How might SYNGR4 serve as a therapeutic target in cancer immunotherapy?

Based on recent research findings, SYNGR4 shows promising potential as a therapeutic target in cancer immunotherapy through several mechanisms:

• Macrophage polarization modulation:

  • Research has demonstrated that SYNGR4 knockdown promotes tumor-associated macrophage polarization toward the pro-inflammatory M1 phenotype

  • This polarization shift increases expression of anti-tumor cytokines (IL-1β, IL-6, TNF-α) while decreasing immunosuppressive cytokines (IL-4, IL-10)

  • Targeting SYNGR4 could potentially convert immunosuppressive tumor microenvironments into pro-inflammatory ones

• Enhanced T cell responses:

  • SYNGR4 overexpression correlates with decreased CD8+ T cell and central memory T cell infiltration

  • Therapeutic inhibition could potentially restore cytotoxic T cell function within tumors

  • Analysis using the TIDE algorithm suggests breast cancers with SYNGR4 overexpression may have higher responsiveness to immunotherapy

• Combination therapy approaches:

  • Anti-SYNGR4 therapies could potentially synergize with existing checkpoint inhibitors

  • Dual targeting of SYNGR4 and pathways regulating Th1/Th2 balance might enhance therapeutic efficacy

  • Antibody-drug conjugates targeting SYNGR4 could deliver immunomodulatory payloads directly to tumor cells

• Biomarker potential:

  • SYNGR4 expression levels could serve as predictive biomarkers for immunotherapy response

  • Stratification of patients based on SYNGR4 expression might identify those most likely to benefit from specific immunotherapeutic approaches

• Delivery strategies:

  • RNA interference therapies targeting SYNGR4 mRNA could be delivered via nanoparticles

  • Small molecule inhibitors disrupting SYNGR4 function could be developed based on structural studies

  • Engineered T cells targeting SYNGR4-expressing tumor cells represent another potential approach

These therapeutic strategies warrant further investigation, particularly given the observed effects of SYNGR4 on breast cancer tumor microenvironments and the potential applicability to other cancer types where SYNGR4 is overexpressed .